ARTICLE | Company News

ZymoGenetics, Bayer deal

January 4, 2010 8:00 AM UTC

Bayer returned all rights, excluding Canada, to Recothrom recombinant human thrombin following a review of its portfolio. Bayer will continue to market the biologic in Canada and receive a maximum $12 million yearly commission on U.S. sales through Dec. 31, 2011, but is no longer eligible for bonus payments in the U.S. ZymoGenetics will be responsible for all regulatory filings outside of Canada and is no longer eligible for $16 million in ex-U.S. regulatory milestones. ...